NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

DocLee,

I suggest you take a look when the trial was started. We cannot expect to have the matching magnitude like fingerprint as the technology has been evolving with time.

I don't need to mention again about the fact that RevImmune is solely owned by LP.
The most important part is that the DC vaccine as mentioned in the paper had amazing efficacy on the patients with three types of tough cold tumors, which without doubt means DCs can be pulsed with tumor-associated antigens (a lot of them). No other technologies can make DC vaccines pulsed with tumor-associated antigens except the technology owned by NWBO.

If you take a look closely at those authors, can you see any one of them could be the developer of new technology? Would any of them apply for new funding if they developed such an amazing new technology? Would they license the technology to a company for commercialization just like what NCI did to lifileucel?

Again there is no difference in terms of being able to pulse dendritic cells with plenty tumor-associated antigens.